Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of targeted small molecule therapeutics for the treatment of cancer. The company develops NXP800, an oral small molecule inhibitor of the Heat Shock Factor 1 pathway, a signaling pathway in the initiation and progression of various cancers; and NXP900 program, an oral small molecule designed to inhibit the SRC and YES1 kinases. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey. The company trades on NCM exchange. The company headquarter is located in Fort Lee, United States. The company was established in the 2020.

TickerNVCT
Long NameNuvectis Pharma, Inc.
Short NameNuvectis Pharma, Inc.